WO1996021446A1 - Composition pharmaceutique a proprietes antialcooliques et nootropes - Google Patents

Composition pharmaceutique a proprietes antialcooliques et nootropes Download PDF

Info

Publication number
WO1996021446A1
WO1996021446A1 PCT/RU1996/000006 RU9600006W WO9621446A1 WO 1996021446 A1 WO1996021446 A1 WO 1996021446A1 RU 9600006 W RU9600006 W RU 9600006W WO 9621446 A1 WO9621446 A1 WO 9621446A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
sublingual
treatment
patients
fact
Prior art date
Application number
PCT/RU1996/000006
Other languages
English (en)
Russian (ru)
Inventor
Irina Alexeevna Komissarova
Julia Vasilievna Gudkova
Tatyana Dmitrievna Soldatenkova
Tatyana Tikhonovna Kondrashova
Natalya Mikhailovna Burbenskaya
Original Assignee
Irina Alexeevna Komissarova
Julia Vasilievna Gudkova
Soldatenkova Tatyana Dmitrievn
Tatyana Tikhonovna Kondrashova
Burbenskaya Natalya Mikhailovn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irina Alexeevna Komissarova, Julia Vasilievna Gudkova, Soldatenkova Tatyana Dmitrievn, Tatyana Tikhonovna Kondrashova, Burbenskaya Natalya Mikhailovn filed Critical Irina Alexeevna Komissarova
Priority to JP8521587A priority Critical patent/JPH09510738A/ja
Priority to US08/704,745 priority patent/US5798371A/en
Priority claimed from FR9608205A external-priority patent/FR2750605B1/fr
Publication of WO1996021446A1 publication Critical patent/WO1996021446A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Definitions

  • the area of technology The emerging invention is related to the field of medicine, and more specifically, to the new pharmaceutical industry of the United States and the United States.
  • ⁇ nas ⁇ yaschee v ⁇ emya reduction ⁇ ebleniya al ⁇ g ⁇ lya, ⁇ - n ⁇ si ⁇ eln ⁇ leg ⁇ d ⁇ s ⁇ igae ⁇ sya ⁇ e ⁇ a ⁇ a ⁇ ami in ⁇ y or in ⁇ y s ⁇ e ⁇ eni ⁇ bladayuschimi al ⁇ g ⁇ le ⁇ d ⁇ bnym e ⁇ e ⁇ m ( ⁇ an ⁇ vili- za ⁇ ami, ba ⁇ bi ⁇ u ⁇ a ⁇ ami, G ⁇ , an ⁇ igis ⁇ aminnymi s ⁇ eds ⁇ va- E with ⁇ an ⁇ vilizi ⁇ uyuschim deys ⁇ viem).
  • ⁇ i administered chel ⁇ ve ⁇ u is ⁇ lzu- go ⁇ sya ⁇ a ⁇ ⁇ las ⁇ iches ⁇ y ma ⁇ e ⁇ ial or sluzha ⁇ is ⁇ chni ⁇ ami amin ⁇ g ⁇ u ⁇ for ⁇ dde ⁇ zhaniya az ⁇ is ⁇ g ⁇ ⁇ anev ⁇ g ⁇ balance.
  • compositions from a separate amino acid because of the inadequate dose did not receive medical treatment (except for C-excluding b-potassium chloride). 0 This indicates that there are no medical devices in the product range even if the device is equipped with a wrap-around device.
  • the claimed invention is a new one and has not been described in the literature.
  • the main invention lies in the task of creating a new medicinal com- pensation, having a newly-born anti-aggressive, high inactive activity.
  • a component was created which contains active substances of amine and vitamins, which is free of charge.
  • the product can be used in the form of tablets and a boot. It is preferable to use it in the form of a sublingual tablet, and, therefore, one of the drug tablets contains
  • one tablet contains: * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  • the active ingredients of the product are:
  • the claimed substances are the amino acid L-terein and vitamin ⁇ ⁇ .
  • vitamin ⁇ ⁇ 10 (optional) forms of vitamin ⁇ ⁇ : pyridoxine phosphate, pyridoxalphosphate and pyridoxamine. These compounds and connections in an organism are easily converted into a friend.
  • the main form of the complex is a pyroxalphosphate, which is a part of the active center of the business of the enzyme complex
  • ⁇ d ⁇ ug ⁇ y ⁇ a ⁇ eg ⁇ ii is ⁇ y ⁇ uemy ⁇ (64 ⁇ d ⁇ s ⁇ a - ucha- schi ⁇ sya 16-17 le ⁇ in ⁇ .ch yun ⁇ shey 46 and 18 devushe ⁇ ) izuchal ⁇ s zayavlyaem ⁇ y ⁇ m ⁇ zitsii influence on sam ⁇ chuvs ⁇ vie, em ⁇ tsi ⁇ nal- n ⁇ e s ⁇ s ⁇ yanie, ⁇ si ⁇ - ⁇ izi ⁇ l ⁇ giches ⁇ ie ⁇ ea ⁇ tsii, ums ⁇ vennuyu 10 ⁇ ab ⁇ s ⁇ s ⁇ bn ⁇ s ⁇ .
  • s ⁇ e ⁇ eni s ⁇ tsialn ⁇ y ada ⁇ i ⁇ vann ⁇ s ⁇ i and vege ⁇ a ⁇ ivn ⁇ y s ⁇ abiln ⁇ s ⁇ i is ⁇ lz ⁇ valis s ⁇ etsialnye ⁇ es ⁇ y ⁇ g ⁇ ammy mezhduna ⁇ dny ⁇ ⁇ m ⁇ le ⁇ sny ⁇ ⁇ bsled ⁇ vany ⁇ d ⁇ s ⁇ v ⁇ i 3 '. ⁇ t ⁇ gek ⁇ ⁇ 1989).
  • the investigated groups of companies also had a 35 increase, which, due to the influence of the claimed combination, 40% of the pulse rate was observed (if available)
  • the table will kill the memory and its dynamics in applications with different types of reaction to the declared memory.
  • the experimental (basic) group of patients received the claimed combination: in the first days, 1-3 tablets per day of 3 times a day (a single dose of 0.1-0.3 g, daily - 0.3-0; on the other hand, 1-2 tablets at a dose of 3 times a day, each dose of 0.1-0.2 g, daily 0.3-0.6 g) for 3-4 weeks.
  • the second stage involved the dynamic registration of EEG parameters in the course of the treatment. After the registration of physical bioelectrical activity, the test subject received a pharmacological treatment of 5 or place, then, during 20 minutes, the test was not performed. ⁇ Further studies were carried out after 60, 90, 120 and 240 minutes after the end of the operation.
  • EEG ⁇ ablitsa 7
  • ch ⁇ on ⁇ yazhenii dvu ⁇ chas ⁇ v ⁇ sle ⁇ dn ⁇ a ⁇ n ⁇ g ⁇ ⁇ iema zayavlyaem ⁇ y ⁇ ml ⁇ zitsii u ⁇ azannye ⁇ endentsii s ⁇ a- nyayu ⁇ sya, ⁇ ya ⁇ ⁇ ntsu issled ⁇ vaniya ⁇ mechae ⁇ sya ne ⁇ e reduction m ⁇ schn ⁇ s ⁇ i al ⁇ a 5- ⁇ i ⁇ ma in ⁇ vedenii with ⁇ av ⁇ g ⁇ ⁇ - lusha ⁇ iya.
  • ⁇ Indicated groups of the claimed composition began with a sublingual dose of 0.1–0.3 g per day for 4–5 days without prescribing any relevant medications.
  • ⁇ ⁇ e ⁇ v ⁇ y g ⁇ u ⁇ e b ⁇ lny ⁇ ⁇ d influence zayavlyaem ⁇ y ⁇ m- ⁇ zitsii ⁇ is ⁇ dila ⁇ edu ⁇ tsiya ⁇ a ⁇ i ⁇ ⁇ yavleny, ⁇ a ⁇ ch ⁇ ee- me ⁇ naya ⁇ anim ⁇ s ⁇ , ⁇ ev ⁇ ga, ⁇ azd ⁇ azhi ⁇ eln ⁇ s ⁇ , na ⁇ yazhen- n ⁇ s ⁇ , v ⁇ ss ⁇ anavlivalsya s ⁇ n, vn ⁇ v ⁇ yavlyalas uve ⁇ enn ⁇ s in sv ⁇ i ⁇ sila ⁇ , b ⁇ lnye ⁇ mechali znachi ⁇ eln ⁇ e improvement sv ⁇ eg ⁇ ⁇ iziches ⁇ g ⁇ s ⁇ s ⁇ yaniya, ⁇ adali thought ⁇ the safety of treatment,
  • the average age of this group of patients was 34.0+ 1.8 years (from 26 to 43 years), the average duration of the disease is 7.7 + 1.7 years (from 3 to 20 years), duration is 2.2 + 5 days (from 2 to 14 days), the expressed results of 35 5.8 + 0.28 points (from 4 to 7 points).

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique antialcoolique et nootrope destinée à être administrée par voie sublinguale et contenant, comme base active, l'acide aminé L-tréonine ou un sel pharmacologiquement acceptable de celui-ci et de la vitamine B6. L'invention porte également sur un procédé de réduction et d'élimination de la dépendance pathologique à l'alcool et de traitement du syndrome de sevrage alcoolique ainsi que sur une méthode destinée à accroître l'attention. Cette méthode consiste à administrer par voie sublinguale une dose efficace de la composition selon l'invention.
PCT/RU1996/000006 1995-01-13 1996-01-04 Composition pharmaceutique a proprietes antialcooliques et nootropes WO1996021446A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP8521587A JPH09510738A (ja) 1995-01-13 1996-01-04 禁酒及びヌートロピック効果を付与された医薬組成物
US08/704,745 US5798371A (en) 1995-01-13 1996-01-04 Pharmaceutical composition endowed with an antialcoholic and nootropic effect

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU9595100307A RU2097034C1 (ru) 1995-01-13 1995-01-13 Фармацевтический препарат антиалкогольного и ноотропного действия
RU95100307 1995-01-13
DE19626431A DE19626431B4 (de) 1995-01-13 1996-07-01 Verwendung einer pharmazeutische Komposition mit antialkoholischer und nootroper Wirkung
FR9608205A FR2750605B1 (fr) 1995-01-13 1996-07-02 Composition pharmaceutique a effets antialcooliques et nootropes
CH01664/96A CH691791A8 (de) 1995-01-13 1996-07-03 Pharmazeutische komposition gegen alkoholmissbrauch und mit notroper wirkung.

Publications (1)

Publication Number Publication Date
WO1996021446A1 true WO1996021446A1 (fr) 1996-07-18

Family

ID=27428256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1996/000006 WO1996021446A1 (fr) 1995-01-13 1996-01-04 Composition pharmaceutique a proprietes antialcooliques et nootropes

Country Status (5)

Country Link
JP (1) JPH09510738A (fr)
CH (1) CH691791A8 (fr)
DE (1) DE19626431B4 (fr)
RU (1) RU2097034C1 (fr)
WO (1) WO1996021446A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750605A1 (fr) * 1995-01-13 1998-01-09 Komissarova Irina Alexeevna Composition pharmaceutique a effets antialcooliques et nootropes
DE19626431B4 (de) * 1995-01-13 2011-03-17 Irina Alexseevna Komissarova Verwendung einer pharmazeutische Komposition mit antialkoholischer und nootroper Wirkung

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
JP2018127427A (ja) * 2017-02-10 2018-08-16 味の素株式会社 唾液分泌促進剤、ならびにこれを配合した食品組成物、および口腔用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405629A (en) * 1979-05-07 1983-09-20 Massachusetts Institute Of Technology Process for increasing glycine levels in the brain and spinal cord
US4761429A (en) * 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
EP0342139A2 (fr) * 1988-05-09 1989-11-15 Cortial S.A. Utilisation de l'Aspartate d'Arginine pour la fabrication d'un médicament pour traiter certains troubles de la mémoire
WO1993013764A1 (fr) * 1992-01-10 1993-07-22 Irina Alexeevna Komissarova Preparation pharmaceutique a action antistress, de prevention du stress et nootrope

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
RU2097034C1 (ru) * 1995-01-13 1997-11-27 Ирина Алексеевна Комиссарова Фармацевтический препарат антиалкогольного и ноотропного действия

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405629A (en) * 1979-05-07 1983-09-20 Massachusetts Institute Of Technology Process for increasing glycine levels in the brain and spinal cord
US4761429A (en) * 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
EP0342139A2 (fr) * 1988-05-09 1989-11-15 Cortial S.A. Utilisation de l'Aspartate d'Arginine pour la fabrication d'un médicament pour traiter certains troubles de la mémoire
WO1993013764A1 (fr) * 1992-01-10 1993-07-22 Irina Alexeevna Komissarova Preparation pharmaceutique a action antistress, de prevention du stress et nootrope

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750605A1 (fr) * 1995-01-13 1998-01-09 Komissarova Irina Alexeevna Composition pharmaceutique a effets antialcooliques et nootropes
DE19626431B4 (de) * 1995-01-13 2011-03-17 Irina Alexseevna Komissarova Verwendung einer pharmazeutische Komposition mit antialkoholischer und nootroper Wirkung

Also Published As

Publication number Publication date
RU2097034C1 (ru) 1997-11-27
CH691791A8 (de) 2002-03-15
DE19626431B4 (de) 2011-03-17
DE19626431A1 (de) 1998-01-08
JPH09510738A (ja) 1997-10-28
CH691791A5 (de) 2001-10-31

Similar Documents

Publication Publication Date Title
Ritsner et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study
Nimmerrichter et al. Double-blind controlled trial of γ-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal
US20220273644A1 (en) Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
WO1997015225A1 (fr) Agent therapeutique contre les troubles neurodegeneratifs
Larrison-Faucher et al. Nicotine reduces antisaccade errors in task impaired schizophrenic subjects
TW201340976A (zh) 富含鞣花單寧之萃取物組成物
DE69209414T2 (de) Hirnaktivitätfördernde Zubereitungen
Thompson et al. Non-MAOI antidepressant drugs and cognitive functions: a review
Campbell et al. Lifestyle changes to prevent and control hypertension: do they work? A summary of the Canadian consensus conference
US9730901B2 (en) Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence
Power et al. Brief report: response to methylphenidate in two children with Williams syndrome.
WO1993013764A1 (fr) Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
Myrenfors et al. Moclobemide overdose
WO1996021446A1 (fr) Composition pharmaceutique a proprietes antialcooliques et nootropes
O’Malley et al. Interaction of Ethanol and Oral ANS‐6637, a Selective ALDH2 Inhibitor in Males: A Randomized, Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Cohort Study
Botter A clinical double-blind comparison of maprotiline and amitriptvline in depression
Carroll The etiology and treatment of tobacco-alcohol amblyopia
Birkmayer NADH, the Biological Hydrogen: The Secret of Our Life Energy
US11331319B2 (en) Combination treatment for neuropsychiatric disorders
Kolobaric et al. Rest assured: A melatonin-free supplement improves sleep, associated health outcomes, and overall well-being in a randomized, double-blind, placebo-controlled trial
Hoffer Allergy, depression and tricyclic antidepressants
WO2005002564A1 (fr) Medicament et agent prophylactique administre lors de la consommation d'alcool et de substances psychoactives
BERKWITZ NON-CONVULSIVE ELECTRIC (FARADIC) SHOCK THERAPY OF PSYCHOSES ASSOCIATED WITH ALCOHOLISM, DRUG INTOXICATION AND SYPHILIS: A Psychosomatic Approach in the Treatment of" Reaction of Delirium"
AU2020257108A1 (en) Compound Essential Oil Composition and Use Thereof for Improving Cognition, Sleep and Mood
Meyer-Bahlburg Pilot studies on stimulant effects of capsicum spices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 08704745

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA